.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CG01_Sulbactam.Sulbactam .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CG01_Sulbactam.Sulbactam| name: | Sulbactam |
| ATC code: | J01CG01 | route: | intravenous |
| n-compartments | 2 |
Sulbactam is a beta-lactamase inhibitor used mainly in combination with beta-lactam antibiotics such as ampicillin to extend their spectrum of activity. It is primarily used to treat infections caused by beta-lactamase producing bacteria. Sulbactam is approved and in clinical use today, often as ampicillin/sulbactam.
Pharmacokinetic parameters in healthy adult volunteers (n=12), both sexes, single-dose administration.
Setiawan, E, et al., & Roberts, JA (2023). Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients. Clinical pharmacokinetics 62(4) 573–586. DOI:10.1007/s40262-023-01219-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36853585
O'Donnell, J, et al., & Isaacs, R (2019). Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects. Antimicrobial agents and chemotherapy 63(9) –. DOI:10.1128/AAC.00794-19 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31307978
Soto, E, et al., & Marshall, S (2014). Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. British journal of clinical pharmacology 77(3) 509–521. DOI:10.1111/bcp.12232 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24102758